Drugs / IBI128
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06277752 | Mar 2024 | gout | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06501534 | Jul → Dec 2024 | gout | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-23 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study innoventbio.com ↗ |
| 2025-09-08 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress innoventbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI128 | “IBI128 300mg po. QD(Quaque Die)” NCT06277752 ↗ |
| Action | Inhibit | “selective inhibitor of xanthine oxidase (XO)” NCT06501534 ↗ |
| Route | Oral | “IBI128 300mg po. QD(Quaque Die)” NCT06277752 ↗ |